Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
USD 450 /hr
Hire Dr. Esteban C.
United States
USD 450 /hr
Expert in cancer and viral immunology, vaccine development and T cell based immunotherapy
Profile Summary
Subject Matter Expertise
Services
Writing
Technical Writing
Research
Feasibility Study,
Systematic Literature Review,
Secondary Data Collection
Consulting
Scientific and Technical Consulting
Product Development
Formulation
Work Experience
Professor
Augusta University
November 2013 - Present
Professor
H Lee Moffitt Cancer Center and Research Institute
February 2006 - November 2013
Professor
Mayo Clinic
January 1997 - November 2013
Education
PhD
National University of Mexico (UNAM)
January 1974 - December 1977
Medical Degree (MD)
National University of Mexico (UNAM)
January 1971 - December 1976
Certifications
- Certification details not provided.
Publications
JOURNAL ARTICLE
(2020). Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma . Oncoimmunology.
(2020). Double-Stranded RNA Immunomodulators in Prostate Cancer . The Urologic clinics of North America.
(2020). Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration . Journal for immunotherapy of cancer.
(2020). Poly-ICLC, a multi-functional immune modulator for treating cancer . Seminars in immunology.
(2020). Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw . FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
(2019). PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma . Journal of translational medicine.
(2019). Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model . Nature communications.
(2019). The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice . Cancer immunology, immunotherapy : CII.
(2018). An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion . The Journal of clinical investigation.
(2018). Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma . Oncoimmunology.
(2018). H3K4me3 mediates the NF-κB p50 homodimer binding to the <i>pdcd1</i> promoter to activate PD-1 transcription in T cells . Oncoimmunology.
(2018). Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy . Hepatology (Baltimore, Md.).
(2018). Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice . Cancer immunology, immunotherapy : CII.
(2018). Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition . Cancer immunology research.
(2017). Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer . Nature communications.
(2017). Effective antitumor peptide vaccines can induce severe autoimmune pathology . Oncotarget.
(2017). Cancer immunotherapy: moving forward with peptide T cell vaccines . Current opinion in immunology.